Diateca

Bookmark and Share

Progetto vincitore della Borsa di Studio SISA 2016 - Barale

 

 

Glucagon-like peptide 1 effects on platelets in type 2 diabetes mellitus and hypercholesterolemia: putative role of a lipid-lowering therapy

Cristina Barale

 


Abstract:


Metabolic and hormonal changes characterizing Type 2 Diabetes Mellitus (T2DM) are involved in the pathogenesis of the altered platelet function. Glucagon-like Peptide 1 (GLP-1) is an incretin hormone which exerts pivotal effects on glucose control and also influences cardiovascular system. No information exist on the role of GLP-1 on peculiar aspects of platelet functions in T2DM. Furthermore, data concerning the role of hypercholesterolemia per se in affecting platelet sensitivity to GLP-1 effects are unknown. We have recently found that normally GLP-1 in vitro decreases platelet reactivity and this effect is impaired in platelets from T2DM subjects.

The study will be structured in different protocols aimed at verifying: i) whether the GLP-1-based therapy in T2DM influences platelet reactivity to the pro- and antiaggregating agents; b) whether hypecholesterolemia -in the absence of hyperglycemia- reduces GLP-1 action on platelet function; c) whether the correction of hypercholesterolemia, in subjects affected by primary hypercholesterolemia, improves GLP-1 effects on platelets. In particular, at baseline and after 2 weeks and 3 months of treatment with the GLP-1 analogue Liraglutide in T2DM (n=50) or with the lipid-lowering drug simvastatin in subjects affected by primary hypercholesterolemia (n=50), we will measure parameters of: i) metabolic homeostasis; ii) in vivo platelet activation; iii)inflammation; iv)platelet responses by aggregation tests, evaluation of activation of the inhibitory pathways nitric oxide/cGMP/PKG and cAMP/PKA, activation of the aggregating pathways PI/3K and MAPK and oxidative stress. Moreover, we will also establish whether T2DM and hypercholesterolemia show a normal expression of GLP-1 receptor on platelet surface.

Thus, the project will add new evidences on the role of GLP-1 on platelets in T2DM and eventually to provide an useful therapeutic option to improve also vascular GLP-1 effects.


 

 

 

Presentazione del progetto vincitore di Borsa di Studio SISA - 2016

 

 

 


Area Soci

Eventi

33° Congresso Nazionale


33° Congresso Nazionale

Roma, 24-26 novembre 2019
Save the date

[continua a leggere]

Congresso congiunto SIIA umbro-marchigiana SISA Umbria 2019

Narni (TR), 2 Marzo 2019

[continua a leggere]

Spring Meeting Gruppi Giovani SIIA, SIMI, SISA 2019

Rimini,
28 febbraio - 2 marzo 2019

[continua a leggere]

EAS Advanced Course in Rare Lipid Disease

Cinisello B.mo (Mi), 19 Ottobre 2018

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci S.I.S.A.
Ultimo numero:
Anno 9 • N.4/2018

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2017: 3.318


Newsletter

Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

LIPIGEN
Nuovo sito dedicato al Progetto LIPIGEN

 

Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA

 

PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti